# OnCo record paper-bidard-pada-1-lancet-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-bidard-pada-1-lancet-oncol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-bidard-pada-1-lancet-oncol-2022" ;
  schema:name "Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial"@en ;
  schema:description "Switching hormone therapy when a resistance mutation rose in the blood, before scans showed progression, roughly doubled the time cancer stayed controlled in PADA-1."@en ;
  schema:url <https://onco.cc/key-papers/paper-bidard-pada-1-lancet-oncol-2022/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(22)00555-1>, <https://pubmed.ncbi.nlm.nih.gov/36183733/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(22)00555-1> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Bidard FC, Hardy-Bessard AC, Dalenc F, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/letrozole/> ;
  onco:companies <https://onco.cc/companies/unicancer/> ;
  onco:terms <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/pada-1/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .